Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02475447 · ClinicalTrials.gov registry record · Phase 2
Safety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Pruritus Associated With Atopic Dermatitis
A Phase 2 study, sponsored by Tioga Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 249
- Enrollment target
NCT02475447: Completed Phase 2 study, sponsored by Tioga Pharmaceuticals.
NCT02475447 is a Phase 2 study that has completed, run by Tioga Pharmaceuticals. The registered enrollment target is 249 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (87% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02475447, a Phase 2 study, has completed, sponsored by Tioga Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 249 participants
- Enrollment target
Study Summary
Kappa-opioid receptors mediate the sensation of itch in animals and humans. Asimadoline is an orally active, selective kappa-opioid receptor agonist and has demonstrated efficacy in several preclinical pruritus models. The purpose of this Phase 2 study is to evaluate the safety, tolerability and clinical efficacy of asimadoline in patients with pruritus associated with atopic dermatitis.
Interventions
- DRUG Placebo
- DRUG Asimadoline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 249 participants |
| Start Date | 2015-07 |
| Est. Completion | 2017-06 |
| Phase | Phase 2 |
What the finished NCT02475447 record still lists
NCT02475447 is an interventional study that assigns participants to a tested intervention. The registered 249 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (87% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02475447 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02475447 about?
NCT02475447 is a clinical study titled "Safety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Pruritus Associated With Atopic Dermatitis". Kappa-opioid receptors mediate the sensation of itch in animals and humans. Asimadoline is an orally active, selective kappa-opioid receptor agonist and has demonstrated efficacy in several preclinical pruritus models. The purpose of this Phase 2 study is to evaluate the safety, tolerability and cli...
What is the current status of trial NCT02475447?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 249 participants. The study started on 2015-07. Estimated completion is 2017-06.
What interventions are being tested in trial NCT02475447?
The interventions under investigation include: Placebo (DRUG), Asimadoline (DRUG).
Who is sponsoring clinical trial NCT02475447?
This trial is sponsored by Tioga Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02475447's enrollment target sits among peer trials
249 233rd of 2000 higher than 1,767 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04628767 · 249 participants · Phase 2
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
- NCT05834907 · 249 participants · NA
Hands and Hearts Together
- NCT06067555 · 249 participants · Early Phase 1
Intradermal Influenza Vaccination
- NCT06588478 · 249 participants · Phase 2
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia